120 related articles for article (PubMed ID: 32950397)
1. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates.
Collà Ruvolo C; Stolzenbach LF; Nocera L; Deuker M; Mistretta FA; Luzzago S; Tian Z; Longo N; Graefen M; Chun FKH; Saad F; Briganti A; De Cobelli O; Mirone V; Karakiewicz PI
Urol Oncol; 2021 Jan; 39(1):74.e1-74.e7. PubMed ID: 32950397
[TBL] [Abstract][Full Text] [Related]
2. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
3. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
4. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
[TBL] [Abstract][Full Text] [Related]
5. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
[TBL] [Abstract][Full Text] [Related]
6. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
J Urol; 2021 Jul; 206(1):69-79. PubMed ID: 33683934
[TBL] [Abstract][Full Text] [Related]
7. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients.
Stolzenbach LF; Rosiello G; Pecoraro A; Palumbo C; Luzzago S; Deuker M; Tian Z; Knipper AS; Pompe R; Zorn KC; Shariat SF; Chun FKH; Graefen M; Saad F; Karakiewicz PI
J Natl Compr Canc Netw; 2020 Nov; 18(11):1492-1499. PubMed ID: 33152695
[TBL] [Abstract][Full Text] [Related]
9. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
Jeon HG; Yoo JH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM; Ferrari M; Brooks JD; Chung BI
PLoS One; 2017; 12(11):e0186026. PubMed ID: 29136019
[TBL] [Abstract][Full Text] [Related]
10. Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision.
Sayyid RK; Reed WC; Benton JZ; Lodh A; Woodruff P; Lambert JH; Terris MK; Wallis CJD; Klaassen Z
Urol Oncol; 2021 Nov; 39(11):782.e7-782.e14. PubMed ID: 33766466
[TBL] [Abstract][Full Text] [Related]
11. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study.
Katz JE; Chinea FM; Patel VN; Balise RR; Venkatramani V; Gonzalgo ML; Ritch C; Pollack A; Parekh DJ; Punnen S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):533-538. PubMed ID: 29988097
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer characteristics and cancer-specific mortality of Native American patients.
Deuker M; Knipper S; Pecoraro A; Palumbo C; Rosiello G; Luzzago S; Tian Z; Saad F; Chun F; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):277-285. PubMed ID: 31695139
[TBL] [Abstract][Full Text] [Related]
13. Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy.
Falagario UG; Ratnani P; Lantz A; Jambor I; Dovey Z; Verma A; Treacy PJ; Sobotka S; Martini A; Bashorun H; Ashan M; Wagaskar VG; Lewis S; Cormio L; Carrieri G; Kyprianou N; Mohamed N; Tewari A
J Urol; 2020 Jul; 204(1):82-90. PubMed ID: 31977261
[TBL] [Abstract][Full Text] [Related]
14. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
15. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
16. Racial Disparities in Active Surveillance for Prostate Cancer.
Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
[TBL] [Abstract][Full Text] [Related]
17. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
[TBL] [Abstract][Full Text] [Related]
20. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
